PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies

Phase 1

Completed

• Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm; Chronic Myeloid Leukemia, Blast Crisis; B-cell Acute Lymphoblastic Leukemia; Acute Myelogenous Leukemia
• Interventions: Biological: XmAb14045

• Registration Number: NCT02730312
• Lead Sponsor: Xencor, Inc.

Brief Summary

The purpose of this study is to determine the safety and tolerability of weekly intravenous (IV) administration of XmAb14045 and to determine the maximally tolerated dose (MTD) after the first dose, and then to determine the MTD after second and subsequent infusions.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-03-31
• Study First Submitted QC: 2016-03-31
• Study First Posted: 2016-04-06
• Study Start: 2016-08
• Primary Completion: 2021-09
• Study Completion: 2021-09
• Status Verified: 2022-03
• Last Update Submitted: 2022-03-04
• Last Update Posted: 2022-03-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• Diagnosis of 1 of the following diseases:

  • Primary or secondary AML (including erythroleukemia and eosinophilic leukemia, but excluding acute promyelocytic leukemia)
  • B-cell ALL
  • BPDCN
  • CML in blast phase, resistant or intolerant to tyrosine kinase inhibitor therapy

• Patients with relapsed or refractory disease with no available standard therapy

• ECOG performance status 0-2

• Not a candidate for, or refusing treatment with hematopoietic stem cell transplantation

• Fertile patients must agree to use effective contraception during and for 4 weeks after the last dose of XmAb14045

• Male patients must agree to use highly effective contraception, and refrain from donating sperm during the treatment period and for at least 4 weeks after the last dose of XmAb14045

• Able and willing to complete the entire study

Exclusion Criteria

• Systemic antineoplastic therapy (including cytotoxic chemotherapy and toxin immunoconjugates, but excluding hydroxyurea), unconjugated antibody therapy, or radiotherapy within 2 weeks of the first dose of study treatment, or small molecule kinase inhibitors within 6 elimination half-lives of the first dose of study treatment.
• Prior therapy with CD123- or IL-3R-directed immunotherapies, including monospecific and bsAbs, immunoconjugates, or chimeric antigen receptor- modified T-cell therapy
• Failure to recover from Grade 3 or 4 toxicity from previous treatment (unrelated to malignant bone marrow involvement)
• Known uncontrolled central nervous system involvement by malignant disease
• Absolute blast count ≥10,000/mm3 or symptoms of leukostasis
• Diagnosis of promyelocytic leukemia
• Aspartate aminotransferase or alanine aminotransferase at screening >3.0 x upper limit of normal (ULN) unless considered due to leukemic organ involvement
• Bilirubin >1.5 x ULN, unless prior diagnosis and documentation of leukemic organ involvement, ongoing hemolysis, or Gilbert's syndrome
• Serum creatinine >2.0 x ULN, or estimated creatinine clearance <40mL/min
• Active heart failure or New York Heart Association Class III or IV or Objective Assessment C or D
• History or evidence of a clinically unstable/uncontrollable disorder, condition or disease other than primary malignancy, that in the opinion of the Investigator would pose a risk to the patient safety or interfere with the study evaluation, procedures, or completion
• Evidence of any active, uncontrolled bacterial, viral, parasitic, or systemic fungal infections within 1 week of first dose of study drug
• Positive test for human immunodeficiency virus (HIV) -I or -II antibodies, hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C virus (HCV) antibody (unless HCV viral load test by PCR is negative). HBcAb positivity will be allowed if one or more of the following is true: a) HBsAb is present; b) hepatitis B DNA testing is negative and the patient is receiving hepatitis B reactivation prophylaxis with entecavir, tenofovir, or lamivudine
• Patient is pregnant or breast feeding, or planning to become pregnant while enrolled in the study, up to the End of Study visit
• Patients with substance abuse or other medical or psychiatric conditions that, in the opinion of the Investigator, would confound study interpretation or affect the patient's ability to tolerate or complete the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
XmAb14045	XmAb14045	Biological/Vaccine: XmAb14045 Administered IV weekly up to 8 weeks

Primary Outcome Measures

Name	Time	Method
Identify maximum tolerated (MTD) and/or recommended dose (RD) and schedule for XmAb14045 dosing	Baseline Day 1 through Day 56	Identify maximum tolerated (MTD) and/or recommended dose (RD) and schedule for XmAb14045 dosing
Safety as determined by the number of participants with treatment-related adverse events	Baseline Day 1 through Day 56	Treatment-related adverse events as assessed by CTCAE v4.03

Trial Locations

Locations (9)

Northside Hospital; 🇺🇸 Atlanta, Georgia, United States

Mayo Clinic Jacksonville; 🇺🇸 Jacksonville, Florida, United States

Swedish Cancer Institute; 🇺🇸 Seattle, Washington, United States

Emory University Hospital Midtown; 🇺🇸 Atlanta, Georgia, United States

Winship Cancer Institute, Emory University; 🇺🇸 Atlanta, Georgia, United States

Blood and Marrow Transplant Group of Georgia; 🇺🇸 Atlanta, Georgia, United States

The University of Chicago Medical Center; 🇺🇸 Chicago, Illinois, United States

Wexner Medical Center at The Ohio State University; 🇺🇸 Columbus, Ohio, United States

The University of Texas MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States